PPAR𝛾 Agonists: Potential as Therapeutics for Neovascular Retinopathies
The angiogenic, neovascular proliferative retinopathies, proliferative diabetic retinopathy (PDR), and age-dependent macular degeneration (AMD) complicated by choroidal neovascularization (CNV), also termed exudative or “wet” AMD, are common causes of blindness. The antidiabetic thiazolidinedi...
Saved in:
| Main Authors: | Harrihar A. Pershadsingh, David M. Moore |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/164273 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR𝛾 and Agonists against Cancer: Rational Design of Complementation Treatments
by: Dorina Veliceasa, et al.
Published: (2008-01-01) -
Gastrointestinal Cytoprotection by PPAR𝛾 Ligands
by: Yuji Naito, et al.
Published: (2010-01-01) -
Idealized PPAR𝜸-Based Therapies: Lessons from Bench and Bedside
by: Angélica Amorim Amato, et al.
Published: (2012-01-01) -
Time-Dependent Vascular Effects of Endocannabinoids Mediated by Peroxisome Proliferator-Activated Receptor Gamma (PPAR𝛾)
by: Saoirse E. O'Sullivan, et al.
Published: (2009-01-01) -
Coordinated Regulation of PPAR𝛾 Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity
by: Jérôme Eeckhoute, et al.
Published: (2012-01-01)